adrenal cancer adrenal neoplasm
Conditions
Interventions
None listed
Sponsors
Maxima Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Patients >=18 years. • Histological proven ACC. • The patient has been treated with mitotane > 24 weeks. • Preferably >= 1 or more mitotane measurements >= 14mg/L in the two months prior to inclusion. • Informed consent through the ENS@T database and/or • Informed consent if patients will be approached separately for the donation of one EDTA of blood
Exclusion criteria
Exclusion criteria: • No mitotane dose known at the time of plasma concentration measurements. • Simultaneous treatment with chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A significant association between one or more SNP(s) on the DMET platform and mitotane clearance, corrected for clinical factors of influence as included in the PK-model. | — |
Secondary
| Measure | Time frame |
|---|---|
| - A significant association between the occurrence of serious adverse events and one or more SNP*s on the DMET platform. - A significant association between the period in weeks from initiation of mitotane therapy until first mitotane concentration >=14mg/L and one or more SNP*s on the DMET platform. | — |
Countries
Netherlands
Outcome results
None listed